Abstract
Photoreceptor degeneration decreases light sensitivity and leads to vision loss and various retinal diseases. Neurotrophin-3, originating from Müller glial cells in the retina, plays a key role in protecting photoreceptors from damage induced by light or hypoxia. This neuroprotective approach is important because there are no established methods to regenerate lost photoreceptors. Dietary supplements are one of the useful methods for improving eye health. Eurycoma longifolia (E. longifolia) Jack, which is native to the tropical forest of Malaysia and other Southeast Asian countries, exhibits several medicinal properties. In the present study, we demonstrated that the water extract of E. longifolia roots enhanced neurotrophin-3 gene expression in primary rat Müller cells. Using a stepwise bioassay-guided fractionation and purification of E. longifolia root extracts, we isolated the active compound underlying neurotrophin-3 gene-enhancing activities. Mass spectrometry and nuclear magnetic resonance spectral data identified the compound as eurycomanone. This study provides evidence for the efficacy of E. longifolia and eurycomanone in enhancing neurotrophin-3 expression in Müller cells in vitro. Although the biological significance of this effect and its underlying mechanism remain to be elucidated, this study suggests that E. longifolia may be promising for improving eye health and must be further investigated.
Keywords: neurotrophin-3, photoreceptor, retina, glia, functional food
Introduction
The retina contains a specialized type of neuroepithelial cells called photoreceptors that convert light into electrical signals that the brain can interpret. Degeneration of photoreceptors significantly reduces the light-sensing ability of the retina, leading to vision loss and, consequently, a significantly reduced quality of life.(1) Müller glial cells in the retina provide structural stability and trophic support for photoreceptors.(2,3) They also play an important role in the maintenance of homeostasis in the retina and the maintenance of ions, water, pH levels, and the recycling of neurotransmitters.(2)
Neurotrophin-3 (NT3) belongs to the family of neurotrophic factors, which includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-4, and mainly binds to the tropomyosin receptor kinase C (TrkC). Müller cells are the main source of neurotrophin production, including NT3, which is supplied to adjacent photoreceptor cells. Notably, Müller cells and NT3 are key factors in the protection against and treatment of diseases involving photoreceptor degeneration.(4,5) LaVail et al.(4) reported that the administration of exogenous NT3 considerably protected photoreceptor cells from light-induced damage in rats. Moreover, NT3 produced by Müller cells protects against photoreceptor apoptosis caused by hypoxia-induced oxidative stress in mice.(5) Harada et al.(3) demonstrated that light-induced damage promotes the expression of TrkC but not TrkA, TrkB, or p75NTR in rat photoreceptors. These findings suggest that NT3 may contribute more directly to photoreceptor cell protection compared to NGF or BDNF. Overall, these findings suggest that increased NT3 expression in Müller cells may protect photoreceptors. Moreover, efficient radical treatments to fully restore photoreceptor loss are lacking,(6) warranting the identification of effective neuroprotective approaches against retinal pathologies.
Several studies(7) have demonstrated the efficacy of dietary supplement-based interventions in improving eye health. Carotenoids, such as lutein and zeaxanthin, which are found in plants, have been reported to slow the progression of certain retinal pathologies, such as age-related macular degeneration (AMD).(8) Therefore, it is worth exploring food materials that support eye health. Eurycoma longifolia (E. longifolia) Jack, popularly known as “Tongkat Ali”, native to the tropical forest of Malaysia and other Southeast Asian countries, has several medicinal properties. The roots of E. longifolia have been traditionally used as herbal medicine against several diseases, including male infertility,(9–12) malaria,(13) cancer,(14,15) obesity,(16) mental stress,(17) and muscle disorders.(9) The safety of dietary supplementation of E. longifolia has also been reported.(18,19) Eurycomanone, a quassinoid, is the major active ingredient in E. longifolia. Similar to the crude extracts of E. longifolia, eurycomanone exhibits several physiological activities.(20) Therefore, eurycomanone is often utilized as an indicator of quality in many commercially available E. longifolia extracts.(21)
In our preliminary experiments, we conducted in vitro screening to assess the ability of several plant extracts with the potential to enhance NT3 expression. Subsequently, we observed significant activity in E. longifolia, prompting us to further investigate it. Therefore, in the present study, we aimed to explore the efficacy of the water extract of E. longifolia roots in enhancing NT3 expression in Müller cells and identify its bioactive compound.
Materials and Methods
Materials and reagents
The standardized water extract of E. longifolia root was obtained from a commercial batch of Physta® from ASK Intercity Co., Ltd. (Ichikawa, Japan). The Physta® E. longifolia extract powder contained 0.8–1.5% eurycomanone, ≥35% glycosaponin, ≥30% polysaccharide, and >22% protein. Eurycomanone (CAS 84633-29-4, purity >94.8%) used in the in vitro assay was purchased from FUJIFILM Wako Pure Chemical Corp. (Osaka, Japan). Quassin (CAS 76-78-8; purity >95%) was purchased from Toronto Research Chemicals (Toronto, Canada).
Preparation of a standardized plant extract library for screening
The standardized plant extract library owned by FANCL Corp. (Yokohama, Japan) was used in this study. It was prepared as follows: plant extracts (10 mg) were dissolved in 10 ml dimethyl sulfoxide (FUJIFILM Wako Pure Chemical Corp.), the samples were then centrifuged at 10,000 rpm for 10 min to remove any residues, and the supernatants were collected in microplates and stored at −80°C until assay.
Cell culture
Primary Müller cells were cultured as previously described,(22) Briefly, retinas were isolated from 10 seven-day-old Sprague–Dawley rats (either sex) (Japan SLC, Inc., Hamamatsu, Japan) and collected in 15 ml tubes containing HBSS (Gibco, Thermo Fisher Scientific, Waltham, MA) on ice. The protocol for retinal isolation was approved by the Ethics Committee of Yokohama University of Pharmacy (approval number: 2020-004). The isolated retinas were trypsinized with 0.25% trypsin-EDTA (Sigma-Aldrich, St. Louis, MO) in a 37°C water bath for 30 min, mechanically dissociated into small pieces, and centrifuged at 2,400 rpm for 5 min. The supernatant was aspirated, and the cell pellet was suspended with an appropriate volume of DMEM-F12 (Gibco) containing 10% fetal bovine serum (Corning Inc., Corning, NY) and 1% penicillin/streptomycin (Sigma-Aldrich) (hereafter referred to as complete medium). After filtering with a 100 μm cell strainer (Falcon, Corning), the number of viable cells was counted using trypan blue staining. The cells were then transferred equally into 3–5 cell culture flasks of 75 mm2 (Sumitomo Bakelite, Tokyo, Japan) containing 10 ml complete medium and cultured in an incubator (37°C, 5% CO2). On Day 3, 10 ml of the complete medium was added to each flask. On Day 7, Müller cells were purified according to the incomplete pancreatic enzyme digestion method described by Song et al.(23) On Day 8, purified Müller cells were trypsinized, seeded into cell culture plates, and incubated overnight. All assays using Müller cells were performed on Day 9.
Screening of plant extracts enhancing NT3 expression in retinal Müller cells
Primary Müller cells seeded in 96-well cell culture plates (Falcon) were prepared for screening. The medium was aspirated, and cells were incubated for 90 min in DMEM-F12 containing 1% fetal bovine serum to induce serum-starved condition. Serum starvation was performed to decrease factors in the serum that could affect NT3 expression and to increase responsiveness to the test substance. Each screened material was then added to the medium at a final concentration of 10 μg/ml. After 90 min of treatment, the culture medium was aspirated, and the cells were lysed in RLT buffer (Qiagen, Hilden, Germany). Total RNA was isolated, and a real-time polymerase chain reaction (real-time PCR) was performed to analyze NT3 expression. Materials that showed activity were confirmed for reproducibility and concentration dependence using cells seeded in 48-well cell culture plates (Sumitomo Bakelite).
RNA isolation and real-time PCR
Total RNA was isolated from cultured Müller cells using the Qiagen RNeasy 96 Kit (96-well plate assay) or the RNeasy mini Kit (48-well plate assay) according to the manufacturer’s instructions. DNase I (Qiagen) was used to remove DNA contaminants during RNA purification. Total RNA was reverse transcribed using a PrimeScriptTM RT reagent Kit (Takara Bio Inc., Shiga, Japan) in a 10 μl reaction. Real-time PCR was performed on the QuantStudioTM 5 Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific) using TaqMan Fast Advanced Master Mix and Gene Expression Assays, specifically # Rn00579280_m1 (NT3) and # Rn01462662_g1 (GAPDH). The mRNA expression level of NT3 was normalized to that of the reference housekeeping gene GAPDH in the same samples. Data were analyzed using the comparative Ct method.(24)
Fractionation and isolation of pure compounds from E. longifolia extract
The E. longifolia root extract was purified using a stepwise purification procedure (Fig. 1). The fractions in each step were evaluated for their bioactivity to enhance NT3 expression, and those showing positive effects were subjected to the next step of fractionation. Briefly, the water extract of E. longifolia roots (55 g) was partitioned into ethyl acetate and water fractions using liquid–liquid extraction (LLE; step-I). The biological activity of the ethyl acetate and water fractions was evaluated by adding 10 and 50 μg/ml of the fractions, respectively, to primary Müller cells and assessing their effects on NT3 expression. The active water fraction was further partitioned into n-butanol and water fractions using LLE (step-II), and the resultant fractions were tested for their bioactivity. The active fraction obtained in step-II was treated with 30% ethanol and separated into soluble and insoluble (residue) parts by filtration (step-III). After testing the bioactivity of the fractions at step-III, the soluble part was subjected to a solid-phase extraction using a Strata® C18-E column (55 μm, 70A 50 g/150 ml, Phenomenex Co., Torrance, CA). The column was initially equilibrated with water, followed by elution with a stepwise gradient of 0, 5, 10, 20, and 50% of methanol in water (step-IV). The resulting five fractions were designated fractions A through E (Fr. A–E) and subjected to bioactivity assay. The bioactive fractions were further purified by HPLC using a Capcellpack C18 UG-120 column (5 μm, 20 mm I.D. × 250 mm, Osaka Soda Co., Ltd., Osaka, Japan) (step-V). The separation was carried out using 10% acetonitrile aqueous solution and 0.1% formic acid as the mobile phase and a flow rate of 20 ml/min. Detection was performed at 240 nm using UV spectroscopy. The resulting five fractions were designated fractions BC-1 to BC-5 and subjected to bioactivity assay.
Fig. 1.
Stepwise procedure for the purification of Eurycoma longifolia extract. Active fractions are indicated in bold. LLE, liquid–liquid extraction; Fr, Fraction; Prep-HPLC, preparative HPLC.
Identification of bioactive compounds of E. longifolia
To identify the active compounds in the bioactive fraction of the E. longifolia root extract, the NT3 expression-enhancing fraction obtained by preparative HPLC of the fractions obtained at step-V was subjected to liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance spectroscopy (NMR) analyses. The retention time, UV spectrum, and molecular weight of the compounds were determined using LC-MS (Waters Co., Ltd., Milford, MA) analysis using a CapcellCORE C18 column (2.7 μm, 2.1 mm I.D. × 100 mm; Osaka Soda) with a mobile phase containing 7% acetonitrile aqueous solution and 0.1% formic acid and a flow rate of 0.35 ml/min. MS was performed under the following conditions: Ion mode electrospray ionization (ESI) (+/−); Capillary voltage, 3.0 kV; Cone voltage, 25 V; Desolvation Temp, 400°C; Desolvation gas, 800 L/h; Cone gas, 20 L/h; Acquisition mode, MSSCAM. NMR spectral data were acquired at 298 K and recorded on a JEOL JNM-ECS400 or JNM-ECX-400 spectrometer for 1H (400 MHz) and 13C (100 MHz) spectra. 1H NMR chemical shifts (referenced to residual solvent signals CD2HOD: δH 3.31, CD2HOH: δH 3.31, CHCl3: δH 7.26) and 13C NMR chemical shifts (referenced to the residual solvent signals. CD3OD: δC 49.0, CD3OH: δC 49.0, and CDCl3: δC 77.16) were assigned using a combination. To determine the concentration of the calibration compound, each substance was dissolved in a CD3OD solution. Eurycomanone purchased from Cayman Chemical (Ann Arbor, MI) was used as the standard.
Experimental instrumentation
The analytical equipment used in this study was as follows: NMR spectra were recorded using JEOL JNM-ECS400 and JNM-ECX-400 FT NMR spectrometers. Mass spectra were obtained using a Waters LC-MS system equipped with a photodiode array detector (UPLC-H-Class) and mass analyzer (Xevo-TQD). Preparative LC was performed using a multiple preparative HPLC LC-FORTE/R. LC was performed using a JASCO extrema HPLC system.
Statistical analysis
All data with error bars are expressed as means ± SD of three independent experiments. For comparisons between more than two groups, statistical analyses were performed using a one-way analysis of variance (ANOVA), followed by Dunnett’s test. Differences were considered statistically significant at p<0.05. The data without error bars were expressed as the mean of two independent experiments.
Results
Identification of plant extracts that enhance NT3 expression in Müller cells
Screening of potential NT3 expression enhancers revealed that the water extract of E. longifolia roots enhanced NT3 expression in Müller cells. The addition of 10 and 50 μg/ml E. longifolia extract to the culture medium resulted in a 1.24- and 1.75-fold increase in gene expression, respectively, compared to that in the control (Fig. 2).
Fig. 2.

Effects of Eurycoma longifolia on NT3 expression in Müller cells. Rat primary Müller cells were treated with water extract of E. longifolia root. After incubation for 90 min, cells were lysed, and NT3 mRNA levels were analyzed using real-time PCR. Values are represented as the mean ± SD of three independent experiments, normalized to GAPDH mRNA levels. *p<0.05, **p<0.01 vs control. EL, the water extract of E. longifolia root.
Fractionation and isolation of bioactive compounds from E. longifolia
E. longifolia water extract was partitioned into ethyl acetate and water fractions using LLE. Treatment of primary Müller cells with the resulting water fraction enhanced NT3 expression (Fig. 3A). The water fraction was further partitioned into n-butanol and water using LLE, and the resulting n-butanol fraction was active (Fig. 3B). The soluble portion (4.61 g) of concentrated residue from the n-butanol fraction, treated with 30% ethanol, was also active (Fig. 3C). The soluble part (3.15 g) of the n-butanol fraction was then subjected to solid-phase extraction, and five fractions were obtained. Of these, Fr. B (5% methanol) and Fr. C (10% methanol) were active (Fig. 3D). As their chromatographic profiles showed a similar pattern (Supplemental Fig. 1*), Fr. B and Fr. C were mixed into a single fraction, termed Fr. BC (839.36 mg), and subjected to further purification. Although Fr. A (water) and Fr. D (20% methanol) also showed activity (Fig. 3D), their chromatogram showed multiple small peaks in addition to those common to Fr. B and Fr. C. Thus, Fr. BC was further purified via preparative HPLC and five fractions were obtained—Fr. BC-1 to Fr. BC-5. Of these five fractions, Fr. BC-1, Fr. BC-2, and Fr. BC-3 exhibited activity (Fig. 3E). The chromatogram of these active fractions is shown in Supplemental Fig. 2*. The yields of these three active fractions were 64.12 mg (Fr. BC-1), 8.62 mg (Fr. BC-2), and 16.52 mg (Fr. BC-3). The active compound in Fr. BC-1 with the highest yield was designated compound 1; it exhibited significant activity (Fig. 3F) and was selected for further investigation as a potential bioactive component in E. longifolia.
Fig. 3.
Effects of fractions obtained from Eurycoma extract on NT-3 expression in Müller cells. Rat primary Müller cells were treated with each fraction obtained from the E. longifolia purification process. Each graph shows the effect of (A) fractions obtained from LLE to ethyl acetate and water (step-I), (B) fractions obtained from LLE to n-butanol and water (step-II), (C) the soluble and insoluble parts separated from the n-butanol layer treated with 30% ethanol (step-III), added at 10 μg/ml respectively, (D) fractions obtained from solid-phase extraction of the soluble part and elution using a stepwise gradient of 0, 5, 10, 20, and 50% methanol (step-IV), and (E) the fractions obtained from preparative HPLC of Fr. BC (step-V). (F) Confirmed result of the activity of Fr. BC-1. After incubation for 90 min, the cells were lysed, and NT-3 expression levels were analyzed via real-time PCR. Data values without error bars are expressed as the mean of two independent experiments, normalized to GAPDH mRNA levels (A–E). Data values with error bars are represented as the mean ± SD of three independent experiments, normalized to GAPDH mRNA levels (F). *p<0.05, **p<0.01 vs control. EL, the water extract of E. longifolia root; LLE, liquid–liquid extraction; EtOAc, ethyl acetate; BuOH, n-butanol; EtOH, ethanol; MeOH, methanol.
Identification of the bioactive principle
Fr. BC-1 was concentrated, and the residue was collected to obtain compound 1, a colorless powder. From 55 g of E. longifolia root, 64.12 mg of compound 1 was obtained. It was characterized based on LC-MS and NMR data and compared with the literature. Compound 1 exhibited ESI-MS spectra, with peaks at m/z = 409 (M+H) and 407 (M−H). UV spectroscopy showed that compound 1 showed maximum absorbance at 244 nm (Waters LC-MS). The molecular weight of compound 1 was determined to be 408.4, which is the same as that of the quassinoid eurycomanone (MW: 408.4),(25) a known component of E. longifolia. Furthermore, the LC-MS retention time and UV spectrum of compound 1 showed the same profile as those of commercial eurycomanone used as a standard. Compound 1 was further characterized using NMR to confirm that it was eurycomanone. 1H and 13C NMR spectral data for compound 1 and eurycomanone are shown in Table 1. The 1H-NMR spectrum of compound 1 indicated signals of 4 oxymethine protons δ 3.96 (s, 1H, H-12), 4.31 (s, 1H, H-1), 4.80 (dd, 1H, H-7), and 4.73 (s, 1H, H-15); 3 olefin protons δ 5.44 (d, 1H), 5.56 (d, 1H ), and 6.06 (q, 1H, H-3); and 2 methyl protons δ 2.03 (d, 3H, H-18) and 1.20 (s, 3H, H-19). Two protons of the oxymethylene group (-CH2O-) were determined by resonance signals at δ 3.84 (1H, d, H-20a) and 3.68 (1H, d, H-20b), respectively. The 13C-NMR spectrum of compound 1 displayed a structure with 20 carbons and indicated signals of 4 olefinic carbons δ 121.5 (C-21), 126.0 (C-3), 146.1 (C-13), and 165.2 (C-4); 2 methyl carbons δ 10.0 (C-19) and 22. 9 (C-18); 7 oxygenated carbons δ 71.7 (C-7), 84.3 (C-1), 80.8 (C-12), 79.3 (C-14), and 77.1 (C-15); 2 carbonyl groups δ 174.5 (C-16) and 198.9 (C-2); and acetal carbon δ 109.2 (C-11). Based on these results, compound 1, which showed similar profiles to eurycomanone, was identified as eurycomanone (Table 1 and Fig. 4). The chemical structure of eurycomanone (compound 1) is shown in Fig. 5.
Table 1.
1H and 13C NMR spectral data for compound 1 and commercially available eurycomanone (400 and 100 MHz in CD3CD)
| Compound 1 | Eurycomanone | ||||
|---|---|---|---|---|---|
| No. |
1H δ ppm |
13C δ ppm |
1H δ ppm |
13C δ ppm |
|
| 1 | 4.31 (s, 1H) | 84.3 | 4.31 (s, 1H) | 84.3 | |
| 2 | — | 198.9 | — | 198.9 | |
| 3 | 6.06 (q, J = 1.4 Hz, 1H) | 126.0 | 6.06 (q, J = 1.4 Hz, 1H) | 126.0 | |
| 4 | — | 165.2 | — | 165.2 | |
| 5 | 3.05 (dd, J = 2.7, 12.3 Hz, 1H) | 42.8 | 3.05 (dd, J = 2.7, 12.3 Hz, 1H) | 42.8 | |
| 6 | 2.09 (ddd, J = 2.9, 12.3, 15.0 Hz, 1H) 2.33 (ddd, J = 2.7, 2.9, 15.0 Hz, 1H) |
26.1 | 2.09 (ddd, J = 2.9, 12.3, 15.0 Hz, 1H) 2.33 (ddd, J = 2.7, 2.9, 15.0 Hz, 1H) |
26.1 | |
| 7 | 4.80 (dd, J = 2.9, 2.9 Hz, 1H) | 77.1 | 4.80 (dd, J = 2.9, 2.9 Hz, 1H) | 77.1 | |
| 8 | — | 53.1 | — | 53.1 | |
| 9 | 3.07 (s, 1H) | 48.0 | 3.07 (s, 1H) | 48.0 | |
| 10 | — | 46.5 | — | 46.5 | |
| 11 | — | 109.2 | — | 109.2 | |
| 12 | 3.96 (s, 1H) | 80.9 | 3.96 (s, 1H) | 80.9 | |
| 13 | — | 146.1 | — | 146.1 | |
| 14 | — | 79.3 | — | 79.3 | |
| 15 | 4.73 (s, 1H) | 71.7 | 4.73 (s, 1H) | 71.7 | |
| 16 | — | 174.5 | — | 174.5 | |
| 17 | — | — | — | — | |
| 18 | 2.03 (d, J = 1.4 Hz,3H) | 22.9 | 2.03 (d, J = 1.4 Hz,3H) | 22.9 | |
| 19 | 1.20 (s, 3H) | 10.0 | 1.20 (s, 3H) | 10.0 | |
| 20 | 3.74 (d, J = 9.1 Hz, 1H) 3.89 (d, J = 9.1 Hz, 1H) |
68.0 | 3.74 (d, J = 9.1 Hz, 1H) 3.89 (d, J = 9.1 Hz, 1H) |
68.0 | |
| 21 | 5.44 (d, J = 0.9 Hz, 1H) 5.56 (d, J = 0.9 Hz, 1H) |
121.5 | 5.44 (d, J = 0.9 Hz, 1H) 5.56 (d, J = 0.9 Hz, 1H) |
121.5 | |
Fig. 4.
Overlay display of 1H NMR and 13C NMR spectra of eurycomanone (brown) and compound 1 (green).
Fig. 5.

Chemical structure of eurycomanone.
Confirmation of NT3 expression-enhancing activity of eurycomanone in vitro
Evaluation of the NT3 expression-enhancing activity in primary Müller cells treated with 3, 10, and 30 μM pure eurycomanone revealed enhanced NT3 expression in a dose-dependent manner (Fig. 6A). Furthermore, evaluation of the bioactivity of quassin, the basic ring of quassinoids, showed no activity (Fig. 6B).
Fig. 6.
Effects of eurycomanone and quassin on NT3 expression in Müller cells. Rat primary Müller cells were treated with eurycomanone (A) or quassin (B). After incubation for 90 min, cells were lysed, and NT3 mRNA levels were analyzed using real-time PCR. Values are represented as the mean ± SD of three independent experiments, normalized to GAPDH mRNA levels. *p<0.05, **p<0.01 vs control.
Discussion
In the present study, we demonstrated that the E. longifolia root water extract can enhance NT3 expression in retinal Müller cells. We focused on E. longifolia in this study based on the positive outcomes observed in our preliminary screening experiments, wherein we assessed various plant extracts, including E. longifolia, for their NT3 expression-enhancing properties.
In this study, guided by bioassays using NT3 expression levels as an indicator, E. longifolia water extract was fractionated and purified to isolate the bioactive component. One bioactive compound (Compound 1) from the fraction (Fr. BC-1) was identified with the highest activity and yield. Compound 1 was identified to be eurycomanone using NMR spectroscopy. Eurycomanone enhanced NT3 expression in Müller cells in a dose-dependent manner. However, as shown in Fig. 3, during the purification process, in addition to Fr. BC-1, four fractions—Fr. A, Fr. D, Fr. BC-2, and Fr. BC-3—were also active. Since each peak in Fr. BC-2 and Fr. BC-3 was different from those in Fr. BC-1 (Supplemental Fig. 2*), it was inferred that the activity of Fr. BC-2 and Fr. BC-3 could be due to compounds other than eurycomanone. Both Fr. A and Fr. D of step-IV seemed to contain the peak indicating eurycomanone (Supplemental Fig. 1*, retention time 10 min). However, because of their crude nature and the presence of multiple peaks, the possibility of the presence of other active compounds cannot be ruled out. In addition to eurycomanone, E. longifolia contains various types of quassinoids.(26) In the present study, we demonstrated that quassin, the basic ring of quassinoids, does not contribute to the bioactivity of eurycomanone, indicating that not all chemicals classified as quassinoids induce NT3 expression in retinal Müller cells. However, we could not identify the active structure of eurycomanone conferring the NT3-upregulating activities. Therefore, further studies are required to elucidate the molecular mechanism underlying the NT3 expression-enhancing effects of E. longifolia.
E. longifolia and its main component, eurycomanone, have been reported to exhibit several biological activities. However, our study is the first to demonstrate the effects of E. longifolia on retina-derived cells and the expression of neurotrophic factors. Neurotrophins, such as NT3 and BDNF, have been extensively studied for their central and peripheral neuroprotective effects.(27,28) However, their clinical application presents challenges owing to their short plasma half-life (1.28 and 0.92 min for NT3 and BDNF, respectively) after intravenous administration.(29) To overcome these limitations, the potency of adeno-associated virus (AAV) gene therapy to increase intracellular NT3 levels has been explored for several diseases, including sarcopenia,(30) Charcot-Marie-Tooth disease,(31) and cochlear synaptopathy.(32,33) Furthermore, intravitreal injection of AAV-encoding BDNF or ciliary neurotrophic factor effectively promotes the viability and regeneration of injured adult retinal ganglion cells in rats.(34) While intraocular injections represent an important technique for treating many retinal conditions that can lead to vision loss, they are not less invasive. Therefore, increasing endogenous NT3 expression through orally administered methods, such as dietary sources, could serve as an effective and less invasive neuroprotective strategy. Additionally, Suzumura et al.(35) reported that oral administration of eicosapentaenoic acid ethyl ester and one of its metabolites induces BDNF upregulation in retinal Müller cells and restores retinal function in diabetic retinopathy. These findings suggest that oral administration is an effective drug delivery method for retinal pathologies.
It is important to note that the biological significance of the effect of E. longifolia on enhancing NT3 expression in Müller cells, as observed in this study, needs to be carefully examined. While Müller cells are responsible for maintaining photoreceptors by providing trophic and anti-oxidant support in healthy retinas,(36,37) they can also be activated in response to various pathological conditions.(38) Activated Müller cells proliferate and undergo physiological changes, including alterations in ion transport properties and signaling molecules;(39,40) this process is believed to protect the retina from further damage and facilitate repair after pathological damage.(41) However, under certain conditions, such as diabetic retinopathy, activated Müller cells can exacerbate pathological conditions.(39,40) In diabetic retinopathy, Müller cells have been reported to produce vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor glycoprotein (PEDF), which are involved in diabetes-induced retinal angiogenesis.(42) Thus, Müller cells play crucial roles in the retina under both physiological and pathological conditions. Therefore, the mechanism underlying the ability of E. longifolia to enhance NT3 expression and its potential effects on trophic factors, cytokine, and glutamate metabolism must be investigated in detail. The effects on photoreceptor cell damage should also be verified via co-culture systems.
In this study, we used a standardized water extract of E. longifolia root (Physta®). Although the water extract of E. longifolia root has been used as a food product, its toxicity should be considered for its applications. Rehman et al.(26) reported in their review that the acute oral lethal dose 50 (LD50) of the alcoholic extract of E. longifolia in mice is between 1,500 and 2,000 mg/kg, whereas the acute oral LD50 of the water extract is over 3,000 mg/kg, suggesting that the alcohol extract is more toxic than the water extract. Choudhary et al.(19) reported that the oral NOAEL of E. longifolia water extract in rats is more than 1,000 mg/kg and nontoxic for 90 days. The European Food Safety Authority (EFSA) has recommended that the water extract of E. longifolia can be safely used as a dietary supplement, with no nutritional disadvantages, with a daily intake of up to 200 mg.(43) However, the genotoxicity of E. longifolia is controversial, as it has been shown to induce DNA damage in in vitro mammalian chromosome aberration tests and in vivo comet assays.(43) Therefore, when applying E. longifolia clinically, it is necessary to consider the extraction method and intake amount, as safety is not guaranteed under all conditions.
In conclusion, in this study, we demonstrated that E. longifolia extract can enhance endogenous NT3 expression in Müller cells and that its major compound, eurycomanone, contributes to this activity. We postulate that oral consumption of E. longifolia may contribute to eye health. This study has a few limitations. First, we only focused on the effect of one compound on one neurotrophin at the transcription level in vitro. Furthermore, we were unable to provide experimental evidence for NT3 expression in E. longifolia at the protein level due to the very low expression of NT3. Further research is necessary to ascertain the role of eurycomanone in eye health and elucidate its mechanism of action in enhancing NT3 expression.
Author Contributions
YS: conceptualization; data acquisition; data analysis and interpretation; and writing – original draft, review & editing. MY: data acquisition; data analysis and interpretation (for extraction, purification, and identification of active ingredients); and writing – original draft, review & editing. TW: technical support and study supervision. AY: data acquisition (extraction, purification, and identification of active ingredients). MF: technical and material support. NI: technical and material support. HM: critical revision of the manuscript.
Acknowledgments
We sincerely thank Prof. Dr. Kiyotake Suenaga and Assistant Prof. Dr. Naoaki Kurisawa (Keio University) for the NMR analysis. We would also like to express our gratitude to all our colleagues for their hard work and kind support.
Abbreviations
- BDNF
brain-derived neurotrophic factor
- Fr
fraction
- LC-MS
liquid chromatography-mass spectrometry
- LLE
liquid–liquid-extraction
- NGF
nerve growth factor
- NMR
nuclear magnetic resonance spectroscopy
- NT3
neurotrophin-3
- real-time PCR
real-time polymerase chain reaction
- TrkC
tropomyosin receptor kinase C
Conflict of Interest
YS, MY, TW, and AY are employees of FANCL Corporation (FANCL). This study was funded by FANCL.
References
- 1.Pardue MT, Allen RS. Neuroprotective strategies for retinal disease. Prog Retin Eye Res 2018; 65: 50–76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Bringmann A, Pannicke T, Grosche J, et al. Müller cells in the healthy and diseased retina. Prog Retin Eye Res 2006; 25: 397–424. [DOI] [PubMed] [Google Scholar]
- 3.Harada T, Harada C, Nakayama N, et al. Modification of glial-neuronal cell interactions prevents photoreceptor apoptosis during light-induced retinal degeneration. Neuron 2000; 26: 533–541. [DOI] [PubMed] [Google Scholar]
- 4.LaVail MM, Unoki K, Yasumura D, Matthes MT, Yancopoulos GD, Steinberg RH. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc Natl Acad Sci U S A 1992; 89: 11249–11253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Li N, Zhu Y, Wang J, et al. Müller cells derived neurotrophin-3 inhibits hypoxia-induced photoreceptor apoptosis via the TrkC/ERK pathway. Cytotechnology 2020; 72: 47–56. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Zhang CJ, Ma Y, Jin ZB. The road to restore vision with photoreceptor regeneration. Exp Eye Res 2021; 202: 108283. [DOI] [PubMed] [Google Scholar]
- 7.Medori MC, Naureen Z, Dhuli K, Placidi G, Falsini B, Bertelli M. Dietary supplements in retinal diseases, glaucoma, and other ocular conditions. J Prev Med Hyg 2022; 63 (2 Suppl 3): E189–E199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Mrowicka M, Mrowicki J, Kucharska E, Majsterek I. Lutein and zeaxanthin and their roles in age-related macular degeneration-neurodegenerative disease. Nutrients 2022; 14: 827. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Henkel RR, Wang R, Bassett SH, et al. Tongkat Ali as a potential herbal supplement for physically active male and female seniors--a pilot study. Phytother Res 2014; 28: 544–550. [DOI] [PubMed] [Google Scholar]
- 10.Udani JK, George AA, Musthapa M, Pakdaman MN, Abas A. Effects of a proprietary freeze-dried water extract of Eurycoma longifolia (Physta) and polygonum minus on sexual performance and well-being in men: a randomized, double-blind, placebo-controlled study. Evid Based Complement Alternat Med 2014; 2014: 179529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Low BS, Das PK, Chan KL. Standardized quassinoid-rich Eurycoma longifolia extract improved spermatogenesis and fertility in male rats via the hypothalamic-pituitary-gonadal axis. J Ethnopharmacol 2013; 145: 706–714. [DOI] [PubMed] [Google Scholar]
- 12.Chinnappan SM, George A, Pandey P, Narke G, Choudhary YK. Effect of Eurycoma longifolia standardised aqueous root extract-Physta® on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study. Food Nutr Res 2021; 65: 10.29219/fnr.v65.5647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Kuo PC, Damu AG, Lee KH, Wu TS. Cytotoxic and antimalarial constituents from the roots of Eurycoma longifolia. Bioorg Med Chem 2004; 12: 537–544. [DOI] [PubMed] [Google Scholar]
- 14.Ye G, Xu M, Shu Y, et al. A quassinoid diterpenoid eurycomanone from Eurycoma longifolia Jack rxerts anti-cancer effect through autophagy inhibition. Molecules 2022; 27: 4398. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Hipolith MM, Khor BK, Hirasawa Y, et al. Quassinoids from Eurycoma longifolia Jack roots and their potential inhibitory activity against human benign prostatic hyperplasia cells (BPH-1) and testosterone-induced BPH rat model. Fitoterapia 2023; 166: 105468. [DOI] [PubMed] [Google Scholar]
- 16.Balan D, Chan KL, Murugan D, AbuBakar S, Wong PF. Antiadipogenic effects of a standardized quassinoids-enriched fraction and eurycomanone from Eurycoma longifolia. Phytother Res 2018; 32: 1332–1345. [DOI] [PubMed] [Google Scholar]
- 17.Talbott SM, Talbott JA, George A, Pugh M. Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects. J Int Soc Sports Nutr 2013; 10: 28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Ming YK, Zulkawi NB, Choudhary VK, Choudhary YK. Evaluation of the genotoxicity of Eurycoma longifolia aqueous extract (Physta®) using in vitro Ames test and in vivo mammalian micronucleus test. Int J Pharm Pharm Sci 2015; 7: 367–371. [Google Scholar]
- 19.Choudhary YK, Bommu P, Ming YK, Zulkawi NB. Acute, sub-acute, and subchronic 90-days toxicity of Eurycoma longifolia aqueous extract (Physta) in Wistar rats. Int J Pharm Pharm Sci 2012; 4: 232–238. [Google Scholar]
- 20.Ahmad N, Samiulla DS, Teh BP, et al. Bioavailability of eurycomanone in its pure form and in a standardised Eurycoma longifolia water extract. Pharmaceutics 2018; 10: 90. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Norhidayah A, Vejayan J, Yusoff MM. Detection and quantification of eurycomanone levels in tongkat Ali herbal products. J Appl Sci 2015; 15: 999–1005. [Google Scholar]
- 22.Fischer AJ, Reh TA. Potential of Müller glia to become neurogenic retinal progenitor cells. Glia 2003; 43: 70–76. [DOI] [PubMed] [Google Scholar]
- 23.Song WT, Zhang XY, Xiong SQ, Wen D, Jiang J, Xia XB. Comparison of two methods used to culture and purify rat retinal Müller cells. Int J Ophthalmol 2013; 6: 778–784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001; 25: 402–408. [DOI] [PubMed] [Google Scholar]
- 25.Segaran A, Chua LS, Mohd Ismail NI. A narrative review on pharmacological significance of Eurycoma longifolia jack roots. Longhua Chin Med 2021; 4: 35. [Google Scholar]
- 26.Rehman SU, Choe K, Yoo HH. Review on a traditional herbal medicine, Eurycoma longifolia Jack (Tongkat Ali): its traditional uses, chemistry, evidence-based pharmacology and toxicology. Molecules 2016; 21: 331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Omar NA, Kumar J, Teoh SL. Neurotrophin-3 and neurotrophin-4: the unsung heroes that lies behind the meninges. Neuropeptides 2022; 92: 102226. [DOI] [PubMed] [Google Scholar]
- 28.Pisani A, Paciello F, Del Vecchio V, et al. The role of BDNF as a biomarker in cognitive and sensory neurodegeneration. J Pers Med 2023; 13: 652. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Poduslo JF, Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 1996; 36: 280–286. [DOI] [PubMed] [Google Scholar]
- 30.Ozes B, Tong L, Myers M, Moss K, Ridgley A, Sahenk Z. AAV1.NT-3 gene therapy prevents age-related sarcopenia. Aging (Albany NY) 2023; 15: 1306–1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Ozes B, Myers M, Moss K, et al. AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1. Gene Ther 2022; 29: 127–137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Hashimoto K, Hickman TT, Suzuki J, et al. Protection from noise-induced cochlear synaptopathy by virally mediated overexpression of NT3. Sci Rep 2019; 9: 15362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Cassinotti LR, Ji L, Borges BC, et al. Cochlear neurotrophin-3 overexpression at mid-life prevents age-related inner hair cell synaptopathy and slows age-related hearing loss. Aging Cell 2022; 21: e13708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.LeVaillant CJ, Sharma A, Muhling J, et al. Significant changes in endogenous retinal gene expression assessed 1 year after a single intraocular injection of AAV-CNTF or AAV-BDNF. Mol Ther Methods Clin Dev 2016; 3: 16078. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Suzumura A, Kaneko H, Funahashi Y, et al. n-3 fatty acid and its metabolite 18-HEPE ameliorate retinal neuronal cell dysfunction by enhancing Müller BDNF in diabetic retinopathy. Diabetes 2020; 69: 724–735. [DOI] [PubMed] [Google Scholar]
- 36.Reichenbach A, Bringmann A. New functions of Müller cells. Glia 2013; 61: 651–678. [DOI] [PubMed] [Google Scholar]
- 37.Eastlake K, Luis J, Limb GA. Potential of Müller glia for retina neuroprotection. Curr Eye Res 2020; 45: 339–348. [DOI] [PubMed] [Google Scholar]
- 38.Zhao TT, Tian CY, Yin ZQ. Activation of Müller cells occurs during retinal degeneration in RCS rats. Adv Exp Med Biol 2010; 664: 575–583. [DOI] [PubMed] [Google Scholar]
- 39.Dyer MA, Cepko CL. Control of Müller glial cell proliferation and activation following retinal injury. Nat Neurosci 2000; 3: 873–880. [DOI] [PubMed] [Google Scholar]
- 40.Reichenbach A, Faude F, Enzmann V, et al. The Müller (glial) cell in normal and diseased retina: a case for single-cell electrophysiology. Ophthalmic Res 1997; 29: 326–340. [DOI] [PubMed] [Google Scholar]
- 41.Graca AB, Hippert C, Pearson RA. Müller glia reactivity and development of gliosis in eesponse to pathological conditions. Adv Exp Med Biol 2018; 1074: 303–308. [DOI] [PubMed] [Google Scholar]
- 42.Coughlin BA, Feenstra DJ, Mohr S. Müller cells and diabetic retinopathy. Vision Res 2017; 139: 93–100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA); Turck D, Bohn T, Castenmiller J, et al. Safety of Eurycoma longifolia (Tongkat Ali) root extract as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2021; 19: e06937. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.




